Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00501683 · ClinicalTrials.gov registry record · Phase 1
A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00501683 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 8 participants.
The verdict
NCT00501683, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study will look at the relative amounts of GSK189075 that are found in samples of blood, urine, and feces of healthy male volunteers. Results of the study will be used to understand how the drug is converted in the body and how it is eliminated.
Interventions
- DRUG Radiolabelled GSK189075
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2006-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00501683
The ClinicalTrials.gov registry entry for NCT00501683 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Radiolabelled GSK189075 is the first listed.
NCT00501683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00501683 about?
NCT00501683 is a clinical study titled "A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers". This study will look at the relative amounts of GSK189075 that are found in samples of blood, urine, and feces of healthy male volunteers. Results of the study will be used to understand how the drug is converted in the body and how it is eliminated.
What is the current status of trial NCT00501683?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2006-11.
What interventions are being tested in trial NCT00501683?
The interventions under investigation include: Radiolabelled GSK189075 (DRUG).
Who is sponsoring clinical trial NCT00501683?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.